🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

vTv Therapeutics Inc. VTVT PHARMA

Healthcare · Biotechnology · United States
https://vtvtherapeutics.com
Company Profile ↓
$33.35
+137.70% 1Y
Mkt Cap$131.86M
P/E-44.47
P/B5.02
52W High$42.72
52W Low$14.03
Book Value$6.34
EPS (TTM)$-0.75

Company Overview

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.00.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Trailing 12 Months Year-on-year growth — revenue -100.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-
1 Year:-100.00%

Stock Price Performance

1 Year:+137.70%
6 Months:-5.82%
3 Months:+3.76%
1 Month:-3.64%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 67% of range
$14.03 $42.72
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMABelow
  • RSI (14)53.34 · Neutral
Price Performance
1M-3.64%
3M+3.76%
6M-5.82%
1Y+137.70%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.

CONS

  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-44.47
Industry PE
24.83
Forward P/E
-7.77
PEG Ratio
-
Book Value
$6.34
Price to Book
5.02
P/S
3.41
EV/EBITDA
-33.37
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
-100.00%
Earnings (YoY)
-

Profitability & Returns

ROCE
-39.41%
ROE
-15.80%
ROA
-10.14%
Profit Margin
-12.91%
Op Margin
-25.11%
Gross Margin
22.16%
EPS (Latest Qtr)
$1.65
EPS (TTM)
$-0.75

Balance Sheet & Liquidity

Debt/Equity
0.00
Quick Ratio
12.35
Current Ratio
12.48
Debt
$0
Total Assets
$98.81M
Current Assets
$98.81M
Working Capital
$83.25M

Ownership

Promoter Holding
38.83%
Chg in Prom Hold
-0.15%
FII / Inst Holding
40.75%
Chg in FII Hold
0.00%

Financial Snapshot

Enterprise Value
$131.86M
Total Revenue (TTM)
$36.84M
EBITDA
$-9.24M
Free Cash Flow
$674.38K
Operating Cash Flow
$-16.76M
Shares Outstanding
3.95M
Gross Margin
22.16%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 VTVT vTv Therapeutics Inc. PHARMA 33.35 -44.47 $131.86M 0.00% -39.41% -15.80% - -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -------30.00K13.00K15.00K233.00K2.06M2.47M3.38M4.52M921.00K1.83M8.00K7.00K8.00K-7.00K987.00K9.00K3.00M2.00M9.00K00001.00M00-000036.84M
Cost of Revenue ----------------------------------------
Gross Profit ----------------------------------------
Operating Expenses -----------------------------------6.50M7.72M10.70M7.88M13.58M
Operating Income -7.89M-9.44M-11.09M-13.54M-14.64M-13.53M-13.31M-13.75M-12.62M-11.54M-12.77M-9.13M-8.86M-1.48M-351.00K-4.29M-4.79M-5.42M-6.39M-6.65M-4.20M-2.83M-4.28M-4.67M-1.60M-6.48M-4.03M-5.69M-7.43M-8.00M-5.37M-5.63M-7.16M-6.51M--6.50M-7.72M-10.70M-7.88M23.26M
EBITDA ------------------------------------6.49M-7.72M-10.34M-7.13M23.26M
Interest Expense ----------------------------------0--5.00K1.00K-
Pretax Income ------------------------------------6.22M-7.38M-10.35M-7.14M24.13M
Tax Provision -----------------------------------00000
Net Income -10.41M-4.10M-3.17M-3.85M-4.46M-3.99M-4.05M-4.22M-3.96M-3.65M-4.31M-2.95M-3.07M-796.00K-1.09M-2.15M-2.88M-3.61M-4.40M-4.72M-3.37M-1.53M-4.24M-608.00K-1.09M-7.01M-3.15M-4.26M-4.50M-5.62M-6.65M-4.87M-5.18M-4.78M--5.09M-6.05M-8.70M-7.14M24.13M
Diluted EPS ------------------------------------0.77-0.92-1.08-0.581.65
R&D Expense 5.15M6.57M-11.14M12.08M10.64M-10.96M9.62M8.99M-8.94M8.59M2.70M-2.82M4.23M3.66M-4.20M2.51M1.77M3.10M2.44M2.38M3.13M2.21M3.06M3.94M4.69M2.82M2.65M3.44M3.22M-2.83M4.10M7.02M-8.98M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 976.00K1.55M519.00K634.00K291.00K12.43M2.76M6.41M4.00M2.02M01.02M0
Cost of Revenue -------------
Gross Profit -------------
Operating Expenses ---------24.56M25.50M25.20M32.81M
Operating Income -35.83M-28.90M-38.14M-55.02M-50.68M-19.82M-20.89M-11.85M-21.66M-22.54M-25.50M-24.18M-32.81M
EBITDA ----------24.77M-25.86M-22.52M-31.06M
Interest Expense ---------15.00K13.00K06.00K
Pretax Income ----------24.87M-25.97M-22.61M-31.08M
Tax Provision ---------200.00K0100.00K0
Net Income -48.20M-36.10M-27.50M-16.35M-16.14M-7.91M-13.04M-8.50M-12.99M-19.16M-20.25M-18.46M-26.97M
Diluted EPS ----------10.40-9.71-3.20-3.20
R&D Expense 22.29M17.38M27.24M44.95M39.64M23.04M15.12M11.02M13.32M12.36M13.60M11.55M17.86M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --12.95M91.53M54.49M27.92M8.56M9.27M14.79M-33.24M11.02M38.27M89.90M
Current Assets ----------27.09M10.66M38.11M89.89M
Cash & Equivalents 2.12M1.09M1.38M88.00M51.51M11.76M1.68M1.78M5.75M-12.13M9.45M36.75M88.93M
Inventory --------------
Receivables ---------57.00K173.00K102.00K62.00K-
Total Liabilities --73.67M7.97M22.93M47.52M28.93M18.11M11.00M-27.40M29.57M23.96M25.46M
Current Liabilities --6.86M7.73M11.43M26.93M18.84M13.38M6.39M-7.71M10.62M5.20M6.64M
Long Term Debt --2.11M-11.06M-15.11M5.04M------
Total Debt ----------716.00K529.00K169.00K0
Total Equity -180.17M-303.73M-498.81M-77.97M-90.94M-151.05M-82.85M-49.02M-80.10M--10.74M-24.68M12.20M64.44M
Shares Outstanding ----------2.04M2.08M2.61M3.94M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow ----48.21M-44.56M-26.86M-23.02M-18.00M--16.02M-19.08M-25.31M-25.25M
Investing Cash Flow ----83.00K-25.00K7.00K242.00K0--21.00K4.40M00
Financing Cash Flow ---11.79M7.50M16.61M22.87M19.47M-14.75M12.00M52.61M77.44M
Capital Expenditure -181.00K-33.00K-104.00K-87.00K-57.00K-5.00K-70.00K-0--21.00K---
Free Cash Flow ----48.30M-44.62M-26.86M-23.09M-18.00M--16.04M-19.08M-25.31M-25.25M
Net Change in Cash ----------1.29M-2.68M27.30M52.19M

Ratios (Annual)

Figures in %.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------------
Operating Margin % -3,671.4%-1,865.5%-7,349.1%-8,678.2%-17,416.5%-159.4%-755.9%-184.8%-540.9%-1,116.9%--2,377.6%-
Net Margin % -4,938.8%-2,330.6%-5,298.3%-2,579.2%-5,547.8%-63.6%-471.9%-132.5%-324.3%-949.7%--1,815.3%-
ROE % 15.9%7.2%35.3%18.0%10.7%9.5%26.6%10.6%-178.4%82.1%-151.3%-41.9%
ROCE % --474.7%-45.5%-127.8%-5,129.8%192.9%507.7%-141.1%--88.3%-6,391.5%-73.1%-39.4%

Shareholding Pattern

Insiders
38.83%
Institutions
40.75%
Public Float
66.62%

Top Institutional Holders

#Holder% HeldSharesValue
1 Samsara BioCapital, LLC 7.58% 298.50K $9.49M
2 Millennium Management Llc 6.85% 269.87K $8.58M
3 FMR, LLC 6.61% 260.39K $8.28M
4 Siren, L.L.C. 4.14% 163.00K $5.18M
5 Baker Bros. Advisors, LP 3.77% 148.31K $4.72M
6 Vanguard Capital Management LLC 2.40% 94.46K $3.00M
7 Trails Edge Capital Partners, LP 2.16% 85.19K $2.71M
8 Aisling Capital Management LP 1.27% 50.00K $1.59M
9 Marshall Wace LLP 1.00% 39.56K $1.26M
10 Geode Capital Management, LLC 0.82% 32.47K $1.03M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for VTVT

Google News Wed, 02 Sep 2026

A type 1 diabetes drug developer plans two investor events in September - Stock Titan

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPVUFvYUxtUlFpUXNqTnhOLVRDRDBPLWpEdVlwWGpXY05hTU9FRVNGeURleW5VamZRREozc3BwbUJYVThQVUphakpHa3Y4OUl6VWZCLXVGVk1XQl9HVm5WTExnQlQ5ZDBQYl9VOUQwWi1yV1lJOU4tWkU2dzE3TUxydEppUUhtMWtnSTJzVV…

Google News Wed, 02 Sep 2026

vTv Therapeutics (NASDAQ:VTVT) Stock Price Passes Below 50-Day Moving Average - Should You Sell? - marketbeat.com

<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxQOFdmcjJWWHZnc3FYM0pqcTh0eDY1dTR2QUpDVFhjVldwWUdnb1hlNWNYUEpWR1Z2LWptTUZWYjJuX1JTZ190OTZzY2JFXzktQTAxdTNDRHdtb05ua3B6eVhLYTQtLXYwU3FKWUFWV01kRXZwbmJaRnlTanRsOWgxRG5XakduMHBXU2FOWF…

Google News Fri, 04 Sep 2026

Responsive Playbooks and the VTVT Inflection - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxQZnJ3djAzamdPMkRfWmlrWXVqMFhFazVsY0MtQ1U4WUdmeEFZWlZlbDhqUTVwdFBWNTg4OUZQRUZWRGNQSkgxcjdvUlV3eE52aGxndHltUzF1WlpMZ29LWDBfQzFHcXFPRG5wWFhqbVc1ZUVVS09rMERRb0JoYjZBUTNXVTU1SGVMME9tSF…

Google News hu, 03 Sep 2026

Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT) - The Globe and Mail

<a href="https://news.google.com/rss/articles/CBMikAJBVV95cUxNdjdWM0RNU1JOYVpaSDlDN1BrUVJYNmxjZ3lpMVRzYjdVcXkwaU1oM0hzbF9udWtOSTFVbG1KZXp6eXB5MWNLai1oZWlYTzNhbndLY1Etb3lSeDVtZ2RSckVUUi1NN1h0YmRBdi1VS1pQcnhGUUF5SUpXZWpqdE43U3JuZlFLcC1fc0I4VF…

Google News Sat, 08 Aug 2026

vTv Therapeutics (VTVT) Stock Rises Despite Widening Losses And Zero Revenue - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxQVk1vWnlVSmpCbzBocHJSdEMycEZpa09Sc0xjbEJfMDBaYUpBTk9iRVpDNTF4UThGcHZwSGx5dXN3SFY1a05vakJOZmJWYnNjeXpfN2U2MUhpdENob2ZObC0zT2ltRHB0c25CRUxsTGdveFdUdG9WM2d4czktSzlDQ0VPc3pSQkZnRUNoQ0…

Google News Fri, 04 Sep 2026

vTv Therapeutics Inc (NASDAQ: VTVT) Share Price, VTVT Stock News, VTVT Share Price & Updates - kalkine.com.au

<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE50MDl4SHE0LV9VYmVqcFVkWnhDLWcwYkpBZUxZYURmZ0lndl9aUGZDMV95YjRZenQ3TW5rc1pyQ1BjYmlDZnF4bGdTczVyQmRhRlRjQnpn?oc=5" target="_blank">vTv Therapeutics Inc (NASDAQ: VTVT) Share Price, VT…

VTVT — Frequently Asked Questions

What is the current share price of vTv Therapeutics Inc. (VTVT)?

As of 2026-09-19 21:16 PDT, vTv Therapeutics Inc. (VTVT) trades at $33.35 on NasdaqCM. Its 52-week range is $14.03 to $42.72.

What is the market capitalisation of VTVT?

vTv Therapeutics Inc. (VTVT) has a market capitalisation of $131.86M on NasdaqCM.

What is the P/E ratio of VTVT?

VTVT trades at a trailing price-to-earnings (P/E) ratio of -44.47. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 5.02.

What is the return on equity (ROE) of VTVT?

VTVT has a return on equity (ROE) of -15.80%. Its return on capital employed (ROCE) is -39.41%.

Is VTVT a good stock to buy?

This page provides a data-driven analysis of vTv Therapeutics Inc. (VTVT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space